BPLPHARMABharat Parenterals Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing of general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers eye drops. Bharat Parenterals Limited was incorporated in 1992 and is based in Vadodara, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on BPLPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 35.2% YoY
- • Debt/Equity: 0.47
- • Promoter holding: 79.7%
- • RSI: 54
- • Price vs EMA21: above
- • Trend strength (ADX): 29
Bull case
- • Profit growth: 35.2% YoY
- • Debt/Equity: 0.47
- • Promoter holding: 79.7%
- • RSI: 54
Bear case
- • Revenue growth: -19.2% YoY
- • ROE: -2.5%
- • MACD: bearish
- • Supertrend: bearish
Key risks
- • Weak fundamentals — technical strength may not sustain
- • Revenue growth: -19.2% YoY
- • ROE: -2.5%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹131.11). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.